Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

Stock Information for Akari Therapeutics Plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Akari Therapeutics Plc

Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board
Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference
Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing the Company's Expanded ADC Pipeline
Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026
Akari Therapeutics to Present at the 2026 Biotech Showcase
Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.